» Articles » PMID: 22397366

Who Fans the Flames of Alzheimer's Disease Brains? Misfolded Tau on the Crossroad of Neurodegenerative and Inflammatory Pathways

Overview
Publisher Biomed Central
Date 2012 Mar 9
PMID 22397366
Citations 75
Authors
Affiliations
Soon will be listed here.
Abstract

Neurodegeneration, induced by misfolded tau protein, and neuroinflammation, driven by glial cells, represent the salient features of Alzheimer's disease (AD) and related human tauopathies. While tau neurodegeneration significantly correlates with disease progression, brain inflammation seems to be an important factor in regulating the resistance or susceptibility to AD neurodegeneration. Previously, it has been shown that there is a reciprocal relationship between the local inflammatory response and neurofibrillary lesions. Numerous independent studies have reported that inflammatory responses may contribute to the development of tau pathology and thus accelerate the course of disease. It has been shown that various cytokines can significantly affect the functional and structural properties of intracellular tau. Notwithstanding, anti-inflammatory approaches have not unequivocally demonstrated that inhibition of the brain immune response can lead to reduction of neurofibrillary lesions. On the other hand, our recent data show that misfolded tau could represent a trigger for microglial activation, suggesting the dual role of misfolded tau in the Alzheimer's disease inflammatory cascade. On the basis of current knowledge, we can conclude that misfolded tau is located at the crossroad of the neurodegenerative and neuroinflammatory pathways. Thus disease-modified tau represents an important target for potential therapeutic strategies for patients with Alzheimer's disease.

Citing Articles

TLR4-mediated chronic neuroinflammation has no effect on tangle pathology in a tauopathy mouse model.

Basheer N, Muhammadi M, Freites C, Avila M, Momand M, Hryntsova N Front Aging Neurosci. 2024; 16:1468602.

PMID: 39503044 PMC: 11536299. DOI: 10.3389/fnagi.2024.1468602.


Inhibition of Protease-Activated Receptor-2 Activation in Parkinson's Disease Using 1-Piperidin Propionic Acid.

Quarta S, Sandre M, Ruvoletto M, Campagnolo M, Emmi A, Biasiolo A Biomedicines. 2024; 12(7).

PMID: 39062196 PMC: 11274518. DOI: 10.3390/biomedicines12071623.


A phase 2, open-label study of anti-inflammatory NE3107 in patients with dementias.

Haroon J, Jordan K, Mahdavi K, Rindner E, Becerra S, Surya J Medicine (Baltimore). 2024; 103(30):e39027.

PMID: 39058809 PMC: 11272329. DOI: 10.1097/MD.0000000000039027.


Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease.

Penny L, Lofthouse R, Arastoo M, Porter A, Palliyil S, Harrington C Transl Neurodegener. 2024; 13(1):25.

PMID: 38773569 PMC: 11107038. DOI: 10.1186/s40035-024-00417-w.


A computational model of Alzheimer's disease at the nano, micro, and macroscales.

Chamberland E, Moravveji S, Doyon N, Duchesne S Front Neuroinform. 2024; 18:1348113.

PMID: 38586183 PMC: 10995318. DOI: 10.3389/fninf.2024.1348113.


References
1.
Gomez-Ramos A, Diaz-Hernandez M, Rubio A, Diaz-Hernandez J, Miras-Portugal M, Avila J . Characteristics and consequences of muscarinic receptor activation by tau protein. Eur Neuropsychopharmacol. 2009; 19(10):708-17. DOI: 10.1016/j.euroneuro.2009.04.006. View

2.
Aisen P, Davis K, Berg J, Schafer K, Campbell K, Thomas R . A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology. 2000; 54(3):588-93. DOI: 10.1212/wnl.54.3.588. View

3.
Zilka N, Stozicka Z, Kovac A, Pilipcinec E, Bugos O, Novak M . Human misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the transgenic rat model of tauopathy. J Neuroimmunol. 2009; 209(1-2):16-25. DOI: 10.1016/j.jneuroim.2009.01.013. View

4.
Probst A, Ulrich J, Heitz P . Senile dementia of Alzheimer type: astroglial reaction to extracellular neurofibrillary tangles in the hippocampus. An immunocytochemical and electron-microscopic study. Acta Neuropathol. 1982; 57(1):75-9. DOI: 10.1007/BF00688880. View

5.
Beeri M, Schmeidler J, Lesser G, Maroukian M, West R, Leung S . Corticosteroids, but not NSAIDs, are associated with less Alzheimer neuropathology. Neurobiol Aging. 2011; 33(7):1258-64. PMC: 3130103. DOI: 10.1016/j.neurobiolaging.2011.02.011. View